Compare Crispr Therapeutics AG (CRSP) vs Freeport-McMoRan Inc (FCX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Freeport-McMoRan Inc — how do they compare? Crispr Therapeutics AG trades at $53.39 (market cap $4.88B), while Freeport-McMoRan Inc trades at $73.69 (market cap $102.16B). The key difference: Freeport-McMoRan Inc is far larger — about 20.9× Crispr Therapeutics AG's market cap, and Freeport-McMoRan Inc pays a 0.84% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Freeport-McMoRan Inc for 69 Days on average.
| CRSP | FCX | |
|---|---|---|
Market Cap | $4.88B | $102.16B |
Volume | 2,861,747 | 9,047,971 |
Sector | Health | Basic Materials |
52-Week High | $74.92 | $79.91 |
52-Week Low | $44.34 | $38.65 |
Typical Hold Time | 77 Days | 69 Days |
Enterprise Value | $3.30B | $108.44B |
Dividend Yield | — | 0.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $50.44, down 3.65% amid bearish technical signals. The company shows negative profitability with -$581.60M net income and -4,101.26% net margin for 2025, though Q2 2026 EPS beat expectations. Positive analyst sentiment persists with 57.9% buy ratings and $67.83 consensus target. Recent clinical data presentations and CASGEVY commercial progress provide catalysts.
The stock faces fundamental challenges with persistent losses and negative cash flow from operations, but maintains Wall Street support for its gene-editing pipeline. Key risks include clinical trial outcomes and cash burn, while potential upside hinges on successful drug commercialization and upcoming data readouts through 2026.
FCX trades at $71.13, down 1.02% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $0.68 exceeding the $0.60 estimate. Revenue for 2025 was $25.92B, with net income of $2.20B and an 11.38% net margin. Analyst consensus is a Buy with a $73.27 price target, and recent news highlights copper demand growth driven by AI and data centers.
FCX presents a positive outlook supported by robust copper demand trends and expansion projects, though rising production costs and a bearish technical picture pose near-term risks. The stock offers potential upside to the consensus target, but investors should monitor cost pressures and quarterly execution against expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Freeport-McMoRan Inc
Freeport-McMoRan Inc is an international mining company. It operates geographically diverse assets with proven and probable mineral reserves of copper, gold and molybdenum. The company's portfolio of assets includes the Grasberg minerals district in Indonesia
Read more on FCX →
